17,269 results match your criteria Journal of Nuclear Medicine[Journal]


Brain access of monoclonal antibodies as imaged and quantified by Zr-antibody-PET: perspectives for treatment of brain diseases.

J Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

Amsterdam UMC, Vrije Universiteit Amsterdam, department of Radiology & Nuclear Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220939DOI Listing
February 2019

First clinico-pathological evidence of a non PSMA-related uptake mechanism for Ga-PSMA-11 in salivary glands.

J Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

University Hospital Zürich, Switzerland.

The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is of concern for therapeutic applications of PSMA radioligands, as therapeutic radiation will damage these glands. A better understanding of the uptake mechanism is, therefore, crucial to allow the finding of solutions to reduce toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222307DOI Listing
February 2019

One-step F-labeling and preclinical evaluation of prostate specific membrane antigen trifluoroborate probes for cancer imaging.

J Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

BC Cancer, Canada.

Following the identification of the high-affinity glutamate-ureido scaffold, the design of several potent F- and Ga-labeled tracers has allowed spectacular progress in imaging recurrent prostate cancer by targeting the prostate specific membrane antigen (PSMA). We evaluated a series of PSMA-targeting probes that are F-labeled in a single step for PET imaging of prostate cancer. We prepared eight trifluoroborate constructs for prostate cancer imaging, to study the influence of the linker and the trifluoroborate prosthetic on pharmacokinetics and image quality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.216598DOI Listing
February 2019
1 Read

In Vivo Translation of the CIRPI System---Revealing Molecular Pathology of Rabbit Aortic Atherosclerotic Plaques.

J Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

Stanford University SOM.

Thin-cap fibro atheroma (TCFA), unstable lesions in coronary artery disease (CAD), that prones to rupture resulting in substantial morbidity and mortality worldwide. However, their small size and complex morphological/biological features make early detection and risk assessment difficult. To overcome this limitation, we tested our newly developed catheter-based Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI) system in vivo rabbit abdominal aorta to detect and characterize TCFA. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.222
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.222471DOI Listing
February 2019
5 Reads

Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances.

J Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

H. Lee Moffitt Cancer Center & Research Institute.

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare neoplasms, characterized by a propensity to secrete hormones which cause distinct clinical syndromes. During the past decade, the systemic treatment landscape has improved significantly: new options include everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), sunitinib, an angiogenesis inhibitor, and cytotoxic regimens such as capecitabine and temozolomide. Moreover, the recent approval of the radiolabeled somatostatin analog Lutetium(Lu)-dotatate has had a significant impact on management of neuroendocrine malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.214882DOI Listing
February 2019

Measurement Repeatability of F-FDG-PET/CT versus F-FDG-PET/MRI in Solid Tumors of the Pelvis.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Washington University School of Medicine, United States.

Knowledge of the within-subject variability of F-FDG-PET/MRI measurements is necessary for proper interpretation of quantitative PET or MRI metrics in the context of therapeutic efficacy assessments with integrated PET/MRI scanners. The goal of this study was to determine the test-retest repeatability of these metrics on PET/MRI, with comparison to similar metrics acquired by PET/CT. This prospective study enrolled patients with pathology-proven pelvic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.218735DOI Listing
February 2019
1 Read

Evaluation of C-LSN3172176 as a novel PET tracer for imaging M muscarinic acetylcholine receptors in non-human primates.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Yale University, United States.

The M1 muscarinic acetylcholine receptor (mAChR) plays an important role in learning and memory, and therefore is a target for development of drugs for treatment of cognitive impairments in Alzheimer's disease and schizophrenia. The availability of M1-selective radiotracers for positron emission tomography (PET) will help in developing therapeutic agents by providing an imaging tool for assessment of drug dose-receptor occupancy relationship. Here we report the synthesis and evaluation of C-LSN3172176 (ethyl 4-(6-(methyl-C)-2-oxoindolin-1-yl)-[1,4'-bipiperidine]-1'-carboxylate) in non-human primates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222034DOI Listing
February 2019
1 Read

ImmunoPET imaging to assess target engagement: Experience from Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Hengrui Therapeutics, Inc., United States.

Positron-emission tomography (PET) imaging with radiolabeled drug provides information on tumor uptake and dose-dependent target interaction to support selection of an optimal dose for future efficacy testing. In this immunoPET study of the anti- human epidermal growth factor receptor (HER3) mAb GSK2849330, we investigated the biodistribution and tumor uptake of 89-Zirconium (Zr)-labeled GSK2849330 and evaluated target engagement as a function of antibody mass dose. Zr-GSK2849330 distribution was monitored in 6 patients with HER3-positive tumors not amenable to standard treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.214726DOI Listing
February 2019

Part 1: Introduction to Machine Learning in the Nuclear Medicine Context.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

McMaster University, Canada.

This article, the first in a two-part series, provides an introduction to machine learning in a nuclear medicine context. Part I in this series addresses the history of machine learning and describes common algorithms with illustrations of when these algorithms can be helpful in nuclear medicine. Part II focuses on current contributions of machine learning to our field and addresses future expectations, limitations as well as providing a critical appraisal of what machine learning can and cannot do. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223495DOI Listing
February 2019

The Impact of FcγRI Binding on ImmunoPET.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Hunter College of the City University of New York, United States.

Antibodies are promising vectors for positron-emission tomography (PET) imaging. However, the high uptake of radioimmunoconjugates in non-target tissues such as the liver and spleen hampers their performance as radiotracers. This off-target uptake can lead to suboptimal tumor-to-background activity concentration ratios, decreasing the contrast of images and reducing their diagnostic utility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223636DOI Listing
February 2019
1 Read

The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Stanford University School of Medicine, United States.

Although surgical resection has been the primary treatment modality of solid tumors for decades, surgeons still rely on visual cues and palpation to delineate healthy from cancerous tissue. This may contribute to the high rate (up to 30%) of positive margins in head and neck cancer resections. Margin status in these patients is the most important prognostic factor for overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222810DOI Listing
February 2019
6.160 Impact Factor

New Developments in Dual-labeled Molecular Imaging Agents.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

The University of Texas Health Science Center at Houston, United States.

Intraoperative detection of tumors has had a profound impact on how cancer surgery is performed and addresses critical unmet needs in surgical oncology. Through the use of fluorescent contrast agents, tumor deposits, margins, and residual cancer can be imaged during surgical procedures to complement visual and tactile guidance. The combination of fluorescent and nuclear contrast into a multimodality agent builds upon these capabilities by adding quantitative, non-invasive nuclear imaging capabilities to intraoperative imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.213488DOI Listing
February 2019

Preclinical evaluation and non-human primate receptor occupancy study of F-JNJ-64413739, a novel PET radioligand for P2X7 receptors.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Janssen Research & Development LLC.

The P2X7 receptor is an adenosine triphosphate (ATP)-gated ion-channel, which is abundantly expressed in glial cells within the central nervous system and in the periphery. P2X7 receptor activation leads to the release of the pro-inflammatory cytokine IL-1β in the brain, and antagonism of the P2X7 receptor is a novel therapeutic strategy to dampen ATP-dependent IL-1β signaling. PET ligands for the P2X7 receptor will be not only valuable to assess central target engagement of drug candidates, but also hold promise as surrogate markers of central neuroinflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.212696DOI Listing
February 2019
2 Reads
6.160 Impact Factor

Melanocortin 1 Receptor Targeted Alpha-Particle Therapy for Metastatic Uveal Melanoma.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

Moffitt Cancer Center and Research Institute, United States.

New effective therapies are greatly needed for metastatic uveal melanoma which has a very poor prognosis with a median survival of less than one year. The melanocortin 1 receptor (MC1R) is expressed in 94% of uveal melanoma metastases, and a MC1R specific ligand (MC1RL) with high affinity and selectivity for MC1R was previously developed. The Ac-DOTA-MC1RL conjugate was synthesized in high radiochemical yield and purity, tested in vitro for biostability, MC1R-specific cytotoxicity in uveal melanoma cells, and the La-DOTA-MC1RL analog was tested for binding affinity. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.217
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.217240DOI Listing
February 2019
4 Reads

FIRST HUMAN IMAGING STUDIES WITH THE EXPLORER TOTAL-BODY PET SCANNER.

J Nucl Med 2019 Feb 7. Epub 2019 Feb 7.

University of California, Davis, United States.

Within the EXPLORER consortium, the construction of the world's first total-body PET/CT scanner has recently been completed. The 194 cm axial field of view of the EXPLORER PET/CT scanner is sufficient to cover for the first time, the entire human adult body in a single acquisition in more than 99% of the population and allows total-body pharmacokinetic studies with frame durations as short as 1 second. The large increase in sensitivity arising from total-body coverage as well as increased solid angle for detection at any point within the body allows whole-body 18F-fluorodeoxyglucose (FDG) PET studies to be acquired with unprecedented count density, improving the signal-to-noise ratio of the resulting images. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.226498DOI Listing
February 2019

Clinical outcomes of Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naïve patients with metastatic castration resistant prostate cancer.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik, Bad Berka, Germany.

Lu-labelled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (Lu-PRLT) is an emerging treatment in metastatic castration resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of Lu-PRLT in taxane chemotherapy pretreated (T-pretreated) and taxane chemotherapy naïve (T-naïve) patients with mCRPC. A retrospective analysis was performed on 167 patients with mCRPC who underwent Lu-PRLT between March-2013 and December-2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.216820DOI Listing
January 2019
3 Reads

F-branched chain amino acids: structure-activity relationships and PET imaging potential.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Simon Fraser University, Canada.

The large-neutral amino acid transporters (LAT1-4) are sodium-independent transporters that are widely distributed throughout the body. LAT expression levels are increased in many types of cancer and their expression increases as cancers progress, leading to high expression levels in high grade tumors and metastases. Due to the key role and overexpression of LAT in many types of cancers, radiolabeled LAT substrates are promising candidates for nuclear imaging of malignancies that are not well revealed by conventional radiotracers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220483DOI Listing
January 2019
5 Reads

Detection Rate of F-choline-PET/CT and Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Department of Orthopedics and Traumatology, University Hospital Basel, Switzerland.

Accurate detection of prostate cancer lymph node (LN) metastases (LNM) through PET/CT prior to lymphadenectomy (LA) is crucial for successful therapy. PET/CT with choline-derivatives used to be the standard tool for imaging metastases, whereas Ga-PSMA-(prostate-specific membrane antigen)-PET/CT was introduced recently. Both PET-techniques were investigated with respect to what extent the detection rate of LNM depends on the size of tumor deposits (TD) within LNM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220541DOI Listing
January 2019
11 Reads

Early Postoperative F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Copenhagen University Hospital Rigshospitalet, Denmark.

Complete resection is the treatment of choice for most pediatric brain tumors, but early postoperative MRI for detection of residual tumor may be misleading due to magnetic resonance imaging (MRI) signal changes caused by the operation. PET (positron emission tomography) imaging with amino acid tracers in adults increase the diagnostic accuracy for brain tumors but the literature in pediatric neurooncology is limited. A hybrid PET/MRI system is highly beneficial in children reducing the number of scanning procedures and this is to our knowledge the first larger study using PET/MRI in pediatric neurooncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220293DOI Listing
January 2019

Is True Whole-body FDG-PET/CT required in paediatric lymphoma? An IAEA Multicentre Prospective Study.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

International Atomic Energy Agency, Austria.

Guidelines recommend true whole body (TWB) FDG-PET/CT scans from vertex to toes in paediatric lymphoma patients, although this suggestion has not been validated in large clinical trials. The objective of the study is to evaluate the incidence and clinical impact of lesions outside the "eyes to thighs" regular field of view (R-FOV) in FDG-PET/CT staging (sPET) and interim (iPET) scans in paediatric lymphoma patients. TWB sPET and iPET scans were prospectively performed in paediatric lymphoma patients (11 worldwide centres). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222299DOI Listing
January 2019
3 Reads

Preclinical Evaluation of Benzazepine-Based PET Radioligands - and -C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and Tightrope Walk between GluN2B- and Sigma1 Receptor-Targeted PET Imaging.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland.

The study aims to investigate the performance characteristics of the enantiomers of C-Me-NB1, a recently reported positron emission tomography (PET) imaging probe that targets the GluN2B subtype of NMDA receptors. Reference compound Me-NB1 (Ki hGluN1/GluN2B = 5.4 nM) and the phenolic precursor were prepared via multistep synthesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.221051DOI Listing
January 2019

Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

UniversitätsSpital Zürich, Switzerland.

High-intensity focused ultrasound (HIFU) is a promising new modality for the treatment of localized prostate cancer (PCa). Follow up of patients is recommended with biopsies and multiparametric MRI (mpMRI). However, mpMRI in the postinterventional setting is often false negative. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.221
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.221564DOI Listing
January 2019
2 Reads

Generation of PET attenuation map for whole-body time-of-flight F-FDG PET/MRI using a deep neural network trained with simultaneously reconstructed activity and attenuation maps.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Seoul National University College of Medicine, Korea, Republic of.

We propose a new deep learning based approach to provide more accurate whole-body PET/MRI attenuation correction in comparison to the Dixon-based four-segment method. We use activity and attenuation maps estimated using the maximum likelihood reconstruction of activity and attenuation (MLAA) algorithm as inputs to convolutional neural network (CNN) to learn a CT-derived attenuation map. The whole-body F-FDG PET/CT scan data of 100 cancer patients (38 males and 62 females, age = 57. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.219493DOI Listing
January 2019

Quantitative tumor perfusion imaging with Rubidium-PET/CT in prostate cancer - analytical and clinical validation.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Aarhus University Hospital, Dept of Nuclear Medicine and PET-Centre, Denmark.

The aim of this work was to evaluate Rubidium (Rb) positron emission tomography (PET) / computed tomography (CT) as a diagnostic tool for quantitative tumor blood flow (TBF) imaging in prostate cancer (PCa). Study 1 was performed to evaluate Rb as a marker of TBF, using O-H2O-PET as reference method. Study 2 investigated the ability of Rb uptake measurements to differentiate between PCa and normal prostate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.219188DOI Listing
January 2019
3 Reads

Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations.

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

Clinical Sciences, University of Gothenburg, Sweden.

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. Following extensive preclinical work with α-particle emitting astatine-211 (At), we performed a phase I trial with intraperitoneal (i.p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220384DOI Listing
January 2019

Practical methods for estimating metabolic flux (Ki) to assess response to therapy via static PET scans.

Authors:
Robert K Doot

J Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

University of Pennsylvania, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220913DOI Listing
January 2019
1 Read

P2X7 Radioligand F-PTTP for the Differentiation of Lung Tumor and Inflammation.

J Nucl Med 2019 Jan 17. Epub 2019 Jan 17.

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, China.

Site-specific imaging agents play a key role in tumor targeting, but only a few agents are currently available for inflammation targeting. Since the P2X7 receptor is a promising molecular target for inflammation, we evaluated the potential value of F-labeled tracer F-PTTP for targeting P2X7 receptors, and thus differentiating inflammation against tumors. The radioligand F-PTTP was achieved by a one-steF-trifluoromethylation reaction. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.222
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.222547DOI Listing
January 2019
10 Reads

Quantitative imaging biomarkers for Yttrium-90 distribution on Bremsstrahlung single photon emission computed tomography after resin-based radioembolization.

J Nucl Med 2019 Jan 17. Epub 2019 Jan 17.

Charite University, Yale University School of Medicine, United States.

To identify baseline imaging features in patients with liver cancer that correlate with Yttrium-90 (Y) distribution on post-procedural single photon emission computed tomography (SPECT) and predict tumor response to transarterial radioembolization (TARE). This retrospective study was approved by the institutional review board and included 38 patients with hepatocellular carcinoma (HCC) ( = 23, 18/23 males, mean age 62.39±8. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.219
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.219691DOI Listing
January 2019
5 Reads

Automatic extraction of a reference region for the noninvasive quantification of translocator protein in brain using C-PBR28.

J Nucl Med 2019 Jan 17. Epub 2019 Jan 17.

Severance Hospital, Korea, Republic of.

Brain inflammation is associated with various types of neurodegenerative diseases, including Alzheimer's disease. Quantifying inflammation with PET is a challenging and invasive procedure, especially in frail patients, because it requires blood sampling from an arterial catheter. A widely used alternative to arterial sampling is a supervised clustering algorithm (SVCA), which identifies the voxels with minimal specific binding in the PET images, thus extracting a reference region for noninvasive kinetic modeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.222927DOI Listing
January 2019
3 Reads

In vitro and in vivo characterization of a F-AlF-labeled PSMA ligand for imaging of PSMA-expressing xenografts.

J Nucl Med 2019 Jan 17. Epub 2019 Jan 17.

Radboud university medical center, Netherlands.

The aim of this study was to compare the PSMA-targeting characteristics of PSMA-11, radiolabeled based on chelation of F-AlF, to those of Ga-PSMA-11 to image PSMA-expressing xenografts with PET/CT. Labeling of F-AlF-PSMA-11 via F-AlF-complexation was performed as described by Boschi et al. and Malik et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.218941DOI Listing
January 2019

State of the Art: Precision Cardio-Oncology.

J Nucl Med 2019 Jan 17. Epub 2019 Jan 17.

Division of Cardiology, Department of Medicine, University of Pennsylvania, United States.

Modern oncologic therapies and care have resulted in a growing population of cancer survivors with comorbid, chronic health conditions. As an example, many survivors suffer from an increased risk of cardiovascular complications secondary to cardiotoxic systemic and radiation therapies. In response, the field of cardio-oncology has emerged as an integral component of oncologic patient care, committed to the early diagnosis and treatment of adverse cardiac events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220137DOI Listing
January 2019
2 Reads

Preclinical Evaluation of In-labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-positive Cancer Models.

J Nucl Med 2019 Jan 17. Epub 2019 Jan 17.

University of Saskatchewan, Canada.

Epidermal growth factor receptor I (EGFR) is overexpressed in most cancers of epithelial origin. Antibody drug conjugates (ADCs) with PEGylated-maytansine (PEG-DM1) show promise in vitro and in vivo. However, in vivo biodistribution data for ADCs with PEG-DM1 have not been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.220095DOI Listing
January 2019

Performance characteristics of the digital Biograph Vision PET/CT system.

J Nucl Med 2019 Jan 10. Epub 2019 Jan 10.

University Medical Center Groningen, Netherlands.

This study evaluates the performance of the Siemens Biograph Vision digital PET/CT system (Siemens Healthineers, Knoxville, USA) according to the NEMA NU 2-2012 standard (published by the National Electrical Manufacturers Association (NEMA)) to allow for a reliable, reproducible, and inter-system comparable performance measurement. The new digital PET/CT features silicon photomultiplier (SiPM)-based detectors with 3.2 mm lutetium oxyorthosilicate (LSO) crystals and full coverage of the scintillator area. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.215
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.215418DOI Listing
January 2019
23 Reads

Development and evaluation of a novel kappa opioid receptor agonist as PET radiotracer with superior imaging characteristics.

J Nucl Med 2019 Jan 10. Epub 2019 Jan 10.

Yale University School of Medicine, United States.

Studies have shown kappa opioid receptor (KOR) abnormalities in addictive disorders and other central nervous system diseases and Alzheimer's disease. We have developed the first set of agonist C-GR103545 and antagonist C-LY2795050 radiotracers for positron emission tomography imaging of KOR in human. Nonetheless, C-GR103545 displays protracted uptake kinetics and is not an optimal radiotracer. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.220
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.220517DOI Listing
January 2019
15 Reads

Healthy Tissue Uptake of Ga-Prostate Specific Membrane Antigen (PSMA), F-DCFPyL, F-Fluoromethylcholine (FCH) and F-Dihydrotestosterone (FDHT).

J Nucl Med 2019 Jan 10. Epub 2019 Jan 10.

Amsterdam University Medical Centers, Netherlands.

Positron Emission Tomography (PET) is increasingly used for prostate cancer (PCa) diagnostics. Important PCa radiotracers include Ga-Prostate-Specific Membrane Antigen HBED-CC (Ga-PSMA), F-DCFPyL, F-fluoromethylcholine (F-FCH) and F-dihydrotestosterone (F-FDHT). Knowledge on the variability of tracer uptake in healthy tissues is important for accurate PET interpretation, since malignancy is suspected only if the uptake of a lesion contrasts with its background. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.222
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.222505DOI Listing
January 2019
5 Reads

Impact of P-glycoprotein Function on the Brain Kinetics of the Weak Substrate C-Metoclopramide Assessed with PET Imaging in Humans.

J Nucl Med 2019 Jan 10. Epub 2019 Jan 10.

Medical University of Vienna, Austria.

PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of this efflux transporter in effectively restricting the brain penetration of its substrates across the human blood-brain barrier (BBB). This may not reflect the situation for weak ABCB1 substrates including several antidepressants, antiepileptic drugs and neuroleptics, which exert CNS effects despite being transported by ABCB1. We performed PET with the weak ABCB1 substrate C-metoclopramide in humans to elucidate the impact of ABCB1 function on its brain kinetics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.219972DOI Listing
January 2019

PET imaging of PARP expression using [F]olaparib.

Authors:
Delphine L Chen

J Nucl Med 2019 Jan 10. Epub 2019 Jan 10.

Washington University School of Medicine, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.219733DOI Listing
January 2019

Roadmap for the development and GMP translation of optical tracers cetuximab-800CW and trastuzumab-800CW.

J Nucl Med 2019 Jan 10. Epub 2019 Jan 10.

University of Groningen, University Medical Center Groningen, Netherlands.

Optical molecular imaging using fluorescently labeled monoclonal antibodies is of significant added value to guide surgical or endoscopic procedures. However, development of tracers for clinical trials is complex, and therefore implementation in the clinic is slow. We present a roadmap for development and translation of monoclonal antibody tracers into a current Good Manufacturing Process (cGMP) compliant drug product. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.216556DOI Listing
January 2019
1 Read

2018 SNMMI Highlights Lecture: Oncology and Therapy, Part 2.

Authors:
Andrew Scott

J Nucl Med 2019 Jan;60(1):7N-16N

Director of the Department of Molecular Imaging and Therapy, Austin Health, and Head, Tumor Targeting Laboratory, Olivia-Newton John Cancer Research Institute, Melbourne, Australia.

View Article

Download full-text PDF

Source
January 2019

ABNM Statement on ACMUI Changes in Authorized User Training and Education.

Authors:
George M Segall

J Nucl Med 2019 Jan;60(1):17N

View Article

Download full-text PDF

Source
January 2019

Erratum.

Authors:

J Nucl Med 2019 Jan;60(1):141

View Article

Download full-text PDF

Source
January 2019
1 Read

Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus.

J Nucl Med 2019 Jan;60(1):7-8

Yale School of Medicine, Department of Surgery, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.219386DOI Listing
January 2019
7 Reads

Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin.

J Nucl Med 2019 Jan;60(1):3-6

David Geffen School of Medicine at UCLA, Los Angeles, Californiai.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.223503DOI Listing
January 2019